Veracyte, Inc.
Veracyte, Inc. (VCYT) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · VCYT · as of Jun 9, 2026
Key Statistics
Explore Veracyte, Inc. Data
vcyt stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 20 · Buy rate: 65.0%
The VCYT analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month price target is $47.60, representing +0.70% upside from the current price of $47.27.
Competitors & Peers
vcyt competitorsVCYT
ADPT
APLS
FOLD
IDYA
IRONStock Performance
Full HistoryAbout Veracyte, Inc.
Veracyte, Inc. operates as a global diagnostics company, specializing in the development and commercialization of advanced genomic tests. The company's product portfolio encompasses several key diagno…
what is veracyte, inc. · vcyt stock overview · veracyte, inc. company profile · who is veracyte, inc. ceo · vcyt NASDAQ · veracyte, inc. headquarters · veracyte, inc. business segments
About Stock Overview & Key Data
Veracyte, Inc. (VCYT) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 30, 2013. As of the latest trading session, VCYT stock price is $47.27, with a market capitalization of $3.8B. The stock has returned +69.73% over the past 12 months and +12.28% year-to-date.
According to 20 Wall Street analysts, the consensus rating for Veracyte, Inc. stock is Buy, with an average 12-month price target of $47.60. In fiscal year 2025, Veracyte, Inc. reported revenue of $517.1M and net income of $66.4M. For detailed data — including Veracyte, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Veracyte, Inc. (VCYT) stock price is $47.27. The stock is traded on NASDAQ under the ticker symbol VCYT. The 52-week range is $22.61 – $50.71.